Cyclin D1 in breast cancer pathogenesis
- PMID: 15961768
- DOI: 10.1200/JCO.2005.05.064
Cyclin D1 in breast cancer pathogenesis
Abstract
Taking a perspective on available evidence that emphasizes relevance to human disease, cyclin D1 is solidly established as an oncogene with an important pathogenetic role in breast cancer and other human tumors. However, the precise cellular mechanisms through which aberrant cyclin D1 expression drives human neoplasia are less well established. Indeed, emerging evidence suggests that cyclin D1 might act, predominantly or at least in part, through pathways that do not involve its widely accepted function as a cell cycle regulator. Although therapeutic exploitation of the role of cyclin D1 as a molecular driver of breast cancer carries great promise, it is also suggested that direct targeting of the cyclin D1 gene or gene products may prove more successful than approaches that rely on arguably incomplete knowledge of the oncogenic mechanisms of cyclin D1.
Similar articles
-
A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line.Oncogene. 1994 Jul;9(7):1925-9. Oncogene. 1994. PMID: 8208539
-
Aberrant expression of cell-cycle regulator cyclin D1 in breast cancer is related to chromosomal genomic instability.Genes Chromosomes Cancer. 2002 Jul;34(3):276-84. doi: 10.1002/gcc.10072. Genes Chromosomes Cancer. 2002. PMID: 12007188
-
BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells.Exp Cell Res. 2006 Oct 1;312(16):3120-31. doi: 10.1016/j.yexcr.2006.06.021. Epub 2006 Jun 21. Exp Cell Res. 2006. PMID: 16860316
-
Relevance of cyclin D1 and other molecular markers to cancer chemoprevention.J Cell Biochem Suppl. 1996;25:23-8. J Cell Biochem Suppl. 1996. PMID: 9027594 Review.
-
Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.J Clin Oncol. 2005 Sep 10;23(26):6364-9. doi: 10.1200/JCO.2005.05.019. J Clin Oncol. 2005. PMID: 16155021 Review.
Cited by
-
Clinical Impact of CDK4/6 Inhibitors in De Novo or PR- or Very Elderly Post-Menopausal ER+/HER2- Advanced Breast Cancers.Cancers (Basel). 2023 Oct 26;15(21):5164. doi: 10.3390/cancers15215164. Cancers (Basel). 2023. PMID: 37958338 Free PMC article.
-
Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2- Metastatic Breast Cancer.Cancers (Basel). 2023 Sep 14;15(18):4558. doi: 10.3390/cancers15184558. Cancers (Basel). 2023. PMID: 37760527 Free PMC article.
-
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences.JNCI Cancer Spectr. 2023 Jul 3;7(4):pkad045. doi: 10.1093/jncics/pkad045. JNCI Cancer Spectr. 2023. PMID: 37369022 Free PMC article. Review.
-
Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy.Cells. 2023 Apr 14;12(8):1156. doi: 10.3390/cells12081156. Cells. 2023. PMID: 37190065 Free PMC article. Review.
-
A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans.Front Pharmacol. 2023 Mar 31;14:1116073. doi: 10.3389/fphar.2023.1116073. eCollection 2023. Front Pharmacol. 2023. PMID: 37063263 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
